Solid Lipid Nanoparticle (SLNP) Nammisome formulated with Doxorubicin Prodrug (IC1)
Why a Doxorubicin Prodrug? Doxorubicin is a widely used immunogenic cell death (ICD) inducing chemotherapeutic drug. Doxil, the liposome-encapsulated form of Doxorubicin, shows superiority to free Doxorubicin clinical performance in a variety of neoplastic conditions but still faces challenges. SLNP-IC1 is a novel Prodrug of Doxorubicin formulated as an SLNP, with an improved therapeutic window in preclinical studies and an easier, more reproducible manufacturing process than Doxil.
Target Indications: Liposomal Doxorubicin has been approved in the US for ovarian (disease progression/recurrence after platinum-based chemo), Kaposi’s sarcoma (after the failure of prior systemic chemo or intolerance to it), and multiple myeloma (in combination with bortezomib). SLNP-IC1 may therefore be applicable to these indications, and potentially to other solid tumors as well.
Solid Lipid Nanoparticle
IC1: Doxorubicin Prodrug
Demonstrated Improved Stability, Efficacy, and Safety vs. Doxil
Solid Lipid Nanoparticle formulated IC1 Prodrug dramatically reduces release of free Doxorubicin in human serum compared to liposomal Doxorubicin (LNP-DOX)
Tumor growth inhibition at equivalent dose in vivo (EMT-6 breast cancer murine tumor model) presumably due to enhanced exposure of the nanocarrier associated Doxorubicin
At a significantly higher dose of 12 mg/kg of Doxorubicin equivalents, mice treated with the Nammisome-formulated Doxorubicin exhibit less body weight loss, indicating reduced toxicity